HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies

AIDS Research and Human Retroviruses

Volumn 27, Issue 8, 2011, Pages 877-887

  Chakrabarti, Bimal K ^a,c   Pancera, Marie ^a   Phogat, Sanjay ^a,d   O'Dell, Sijy ^a   McKee, Krisha ^a   Guenaga, Javier ^a,c   Robinson, James ^b   Mascola, John ^a   Wyatt, Richard T ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CELL SURFACE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY; NONNEUTRALIZING ANTIBODY GP41; PROTEIN ANTIBODY; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS SPIKE PROTEIN;

ANTIBODY DETECTION; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; MOLECULAR INTERACTION; MUTAGENICITY; PLASMID; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; VIRUS ASSEMBLY; VIRUS DETECTION; VIRUS MUTANT; VIRUS SHEDDING; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; BLOTTING, WESTERN; FLOW CYTOMETRY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MICE; NEUTRALIZATION TESTS; NIH 3T3 CELLS; PEPTIDE FRAGMENTS; PLASMIDS; PROTEIN BINDING; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; SOLUBILITY; TRANSFECTION;

EID: 79961202021     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0281     Document Type: Article

References (74)

1. Center RJ, Leapman RD, Lebowitz J, Arthur LO, Earl PL, and Moss B: Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol 2002;76(15):7863-7867. (Pubitemid 34761009)
2. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85(7):1135-1148. (Pubitemid 26231178)
3. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312(5996):763-767. (Pubitemid 15195924)
4. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, and Garten W: Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992;360(6402): 358-361. (Pubitemid 23000676)
5. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387(6631):426-430. (Pubitemid 27227210)
6. Willey RL, Bonifacino JS, Potts BJ, Martin MA, and Klausner RD: Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA 1988;85(24):9580-9584. (Pubitemid 19027171)
7. Wu L, Gerard NP, Wyatt R, et al.: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384(6605):179-183. (Pubitemid 26386475)
8. Bolognesi DP and Matthews TJ: HIV vaccines. Viral envelope fails to deliver? Nature 1998;391(6668):638-639. (Pubitemid 28113194)
9. Burton DR and Montefiori DC: The antibody response in HIV-1 infection. AIDS 1997;11(Suppl A):S87-98.
10. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89(2): 263-273. (Pubitemid 27199898)
11. Eckert DM, Malashkevich VN, Hong LH, Carr PA, and Kim PS: Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999;99(1): 103-115. (Pubitemid 29468634)
12. Musey L, Hughes J, Schacker T, Shea T, Corey L, and McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337(18):1267-1274. (Pubitemid 27461281)
13. Scheffold A, Lohning M, Richter A, et al.: Analysis and sorting of T cells according to cytokine expression. Eur Cytokine Netw 1998;9(3 Suppl):5-11.
14. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, and Haas J: Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998;72(2):1497-1503. (Pubitemid 28116938)
15. Bures R, Gaitan A, Zhu T, et al.: Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000;16(18):2019-2035. (Pubitemid 32048460)
16. Hessell AJ, Poignard P, Hunter M, et al.: Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009;15(8): 951-954.
17. Hessell AJ, Rakasz EG, Poignard P, et al.: Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009;5(5):e1000433.
18. Hessell AJ, Rakasz EG, Tehrani DM, et al.: Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the human immunodeficiency virus type 1 (HIV-1) gp41 membrane proximal external region (MPER), protect against SHIVBa-L mucosal challenge. J Virol 2010;84(3): 1302-1313.
19. Manz R, Assenmacher M, Pfluger E, Miltenyi S, and Radbruch A: Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc Natl Acad Sci USA 1995;92(6):1921-1925.
20. Montefiori DC, Robinson WE, Jr., Schuffman SS, and Mitchell WM: Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;26(2):231-235. (Pubitemid 18092291)
21. Muster T, Steindl F, Purtscher M, et al.: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67(11):6642-6647. (Pubitemid 23309131)
22. Ogg GS, Jin X, Bonhoeffer S, et al.: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279(5359):2103-2106. (Pubitemid 28196353)
23. Robey WG, Arthur LO, Matthews TJ, et al.: Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci USA 1986;83(18):7023-7027. (Pubitemid 16002362)
24. Burton DR, Desrosiers RC, Doms RW, et al.: HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5(3):233-236. (Pubitemid 38332116)
25. Haynes BF and Montefiori DC: Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006;5(4):579-595. (Pubitemid 44627888)
26. Li Y, Migueles SA, Welcher B, et al.: Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007;13(9):1032-1034. (Pubitemid 47517505)
27. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-289.
28. Wu X, Yang ZY, Li Y, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329(5993):856-861.
29. Corti D, Langedijk JP, Hinz A, et al.: Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010;5(1):e8805.
30. Gray ES, Moore PL, Bibollet-Ruche F, et al.: 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol 2008; 82(5):2367-2375. (Pubitemid 351293537)
31. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al.: Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006;80(23):11776-11790. (Pubitemid 44788890)
32. Sather DN, Armann J, Ching LK, et al.: Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009;83(2):757-769.
33. Tomaras GD, Yates NL, Liu P, et al.: Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008;82(24): 12449-12463.
34. Grundner C, Mirzabekov T, Sodroski J, and Wyatt R: Solidphase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J Virol 2002;76(7):3511-3521. (Pubitemid 34224552)
35. Pancera M and Wyatt R: Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005;332(1):145-156. (Pubitemid 40127236)
36. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174(2): 407-415.
37. Binley JM, Sanders RW, Clas B, et al.: A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000;74(2): 627-643. (Pubitemid 30036198)
38. Dey AK, David KB, Lu M, and Moore JP: Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 2009;385(1): 275-281.
39. Herrera C, Klasse PJ, Michael E, et al.: The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 2005; 338(1):154-172. (Pubitemid 40835934)
40. Alam SM, Morelli M, Dennison SM, et al.: Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009;106(48):20234-20239.
41. Shen X, Dennison SM, Liu P, et al.: Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc Natl Acad Sci USA 2009;107(13):5972-5977.
42. Daar ES, Li XL, Moudgil T, and Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990;87(17):6574-6578.
43. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science 1992;257(5069): 535-537.
44. Koito A, Harrowe G, Levy JA, and Cheng-Mayer C: Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994;68(4):2253-2259. (Pubitemid 24091903)
45. O'Brien WA, Chen IS, Ho DD, and Daar ES: Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol 1992;66(5):3125-3130.
46. Orloff SL, Kennedy MS, Belperron AA, Maddon PJ, and McDougal JS: Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol 1993;67(3): 1461-1471. (Pubitemid 23067653)
47. Parren PW,WangM, Trkola A, et al.: Antibody neutralizationresistant primary isolates of human immunodeficiency virus type 1. J Virol 1998;72(12):10270-10274. (Pubitemid 28520904)
48. Si Z, Phan N, Kiprilov E, and Sodroski J: Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 2003;19(3):217-226. (Pubitemid 36359887)
49. Sullivan N, Sun Y, Li J, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69(7): 4413-4422.
50. Sullivan N, Sun Y, Sattentau Q, et al.: CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization. J Virol 1998;72(6):4694-4703. (Pubitemid 28215644)
51. Zhang YJ, Fredriksson R, McKeating JA, and Fenyo EM: Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 1997;238(2):254-264. (Pubitemid 28218143)
52. Sattentau QJ, Zolla-Pazner S, and Poignard P: Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology1995;206(1):713-717.
53. Korber BT, Foley F, Kuiken C, Pillai S, and Sodroski J: Numbering positions in HIV relative to HXBc2. In: Human Retroviruses and AIDS (Sodroski J, Ed.). Los Alamos National Laboratory, Los Alamos, NM, 1998, pp. iii-102-iii-103.
54. Koch M, Pancera M, Kwong PD, et al.: Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003;313(2):387-400. (Pubitemid 37045357)
55. Chakrabarti BK, Kong WP, Wu BY, et al.: Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002;76(11):5357-5368. (Pubitemid 34517886)
56. Berlioz-Torrent C, Shacklett BL, Erdtmann L, et al.: Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 1999; 73(2):1350-1361. (Pubitemid 29036790)
57. LaBranche CC, Sauter MM, Haggarty BS, et al.: A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J Virol 1995;69(9):5217-5227.
58. Si Z, Cayabyab M, and Sodroski J: Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J Virol 2001;75(9):4208-4218. (Pubitemid 32410133)
59. Gorny MK and Zolla-Pazner S: Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol 2000;74(13):6186-6192. (Pubitemid 30412992)
60. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, and Burton DR: Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 2003;77(10):5678-5684. (Pubitemid 36538960)
61. Thali M, Furman C, Helseth E, Repke H, and Sodroski J: Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J Virol 1992;66(9):5516-5524.
62. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, and Sodroski J: Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002;76(9):4634-4642. (Pubitemid 34309599)
63. Crooks ET, Jiang P, Franti M, et al.: Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 2008;377(2):364-378.
64. Jeffs SA, Goriup S, Kebble B, et al.: Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004;22(8):1032-1046. (Pubitemid 38221097)
65. Sanders RW, Vesanen M, Schuelke N, et al.: Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002;76(17):8875-8889. (Pubitemid 34864082)
66. Srivastava IK, Stamatatos L, Legg H, et al.: Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 2002;76(6):2835-2847. (Pubitemid 34184870)
67. Yang X, Wyatt R, and Sodroski J: Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001;75(3):1165-1171. (Pubitemid 32094675)
68. Zhang CW, Chishti Y, Hussey RE, and Reinherz EL: Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer. J Biol Chem 2001;276(43):39577- 39585.
69. Barnett SW, Lu S, Srivastava I, et al.: The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75(12):5526-5540. (Pubitemid 32488146)
70. Bower JF, Yang X, Sodroski J, and Ross TM: Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 2004;78(9):4710-4719. (Pubitemid 38501092)
71. Dey B, Svehla K, Xu L, et al.: Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 2009;5(5): E1000445.
72. VanCott TC, Mascola JR, Kaminski RW, et al.: Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997;71(6):4319-4330. (Pubitemid 27204119)
73. Schulke N, Vesanen MS, Sanders RW, et al.: Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 2002;76(15):7760-7776. (Pubitemid 34760999)
74. Binley JM, Sanders RW, Master A, et al.: Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002;76(6):2606-2616. (Pubitemid 34184845)